Contrary to our results, the findings of Ahn et al. [25] and Tang et al. [26] considered DNMT3A R882 as an unfavorable prognostic indicator in AML patients treated with allogeneic HSCT. Here, DNMT3A is linked to acute myeloid leukemia.